Biovica International Ab Class B · OMXSTO:BIOVIC_B
Biovica International Ab Class B — Q4 2025 Earnings Presentation
37 slides from Biovica International Ab Class B's earnings presentation, Jun 18, 2025
Slide 1: Slide 1
Slide 2: Forward Looking-Statements Disclaimer
Forward Looking-Statements Disclaimer The Investor Presentation may contain certain statements that are forward-looking. These statements may refer in particular to the Company's business strategies, its expansion and growth of operations, future events, trends or objectives and expectations, which
Slide 3: Q4 Report
@® Q4Report was} Anders Rylander 3 CEO y A Anders Morén DPD CFO
Slide 4: Agenda
~@ ~~ Agenda ® Biovica Introduction ® Q4 Highlights ® Financial Update ® Summary and Q&A
Slide 5: Q&A Session
Q&ASession _—_ Featured® My questions Financial Analysts on today’s call: to l ee * Johan Unnérus - RedEye se Ask a moderator Questions won't be visible to everyone until a moderator approves them Question??? ] Post as anonymous
Slide 6: Biovica Introduction
® Biovica Introduction
Slide 7: DiviTum TKa
® DiviTum® TKa An early indicator of cancer treatment effectiveness a Progression at month | DiviTum>}— ee TKa ' . : IMAGING Progression at month 4 References: http://biovica.com/technology/publications/ DiviTum® TKa cell proliferation provides quicker evaluation of cancer treatment efficacy.
Slide 8: Strong scientific evidence that is still growing!
Strong scientific evidence that is still growing! 30+ published and peer-reviewed articles St id Iti th f Cancer Area Patients Nr. of studies ® rong evicence Suppor ing © use oO) Breast Cancer 3,039 14 DiviTum® TKa as a clinical biomarker of CDK4/6i response Gastrointestinal 713 4 Malignant Melanoma
Slide 9: Large market potential in first application!
@ Large market potential in first application! BREAST CANCER CS COMMERCIAL : wens = ff VALIDATION —_ He EQ mels) o— MARKET LEADERSHIP COMMERCIAL . 400800 CONSECUTIVE aay ; @uxs | VALIDATION a | ACCELERATION -o— — METASTATIC Rg mUSDiy __, COMMERCIAL VALIDATION, ACCELERATION oOo MARKET LEADERSHIP i oo
Slide 10: Q4 Highlights
Q4 Highlights
Slide 11: Biovica Q4 Highlights
Biovica Q4 Highlights ® US - Biovica collaborates with Tempus to expand the commercial reach of DiviTum® TKa. Organic growth of >30% in Q4! Trend continues first month of Q1. ® Pharma Services: Biovica signs major service agreement with Tier1 pharma and first study work order of 4 MSEK. + Biovica se
Slide 12: US Highlights
US Highlights
Slide 13: Lessons Learned from two years on US Market
Lessons Learned from two years on US Market ® Positives DiviTum® TKa works great in the clinical setting! DiviTum TKa has strong value proposition and in both Metastatic and Early Breast Cancer. Pricing assumptions of an average price of $400 holds well. We're able to attract NCI/NCCN Center oncolog
Slide 14: US Market go-to-market strategy per channel
~@ __ US Market go-to market strategy per channel US Market Clinical Use BC Payers NCI/NCCN Private Insurance Designated O . Medicare / Medicaid Centers ncologists Community tf ft ft f High Value - High Value - High Value - Large volume - Biovica focus Biovica focus Biovica focus Partner Focus
Slide 15: US Sales Performance Q4
@ US Sales Performance Q4 Revenue growth in Q4 24/25: * 120% Q4 23/24 » 230% vs. Q3 24/25 Every month since December have been our best month so far! Increase comes from both existing and new prescribers & institutions. Drivers for growth: » General: SABCS data from Dec-24 strengthens value proposit
Slide 16: Health Care Giant Opportunity Update
Health Care Giant Opportunity Update ® Metastatic Breast Cancer Monitoring Client bill agreement signed in December 2024. Use of DiviTum has started for monitoring of metastatic breast cancer. ® Early Breast Cancer / Adjuvant Treatment Monitoring Protocol for study in early breast cancer for monitor
Slide 17: Prospective IDN Study
Prospective IDN Study: Thymidine Kinase Guided Optimal Therapy in HR+ Early Breast Cancer Objective: Use TKa levels to determine which patients should get adjuvant CDK4/6i treatment. Baseline i] ET 60 months CONTROL N= ~800 pts + HR+, HER2- EBC + Men and Pre/post- menopausal women + Anatomic Stage I
Slide 18: Tempus AI Agreement Highlights
Tempus Al Agreement Highlights ® About Tempus Al Bringing data and Al to healthcare Listed on NASDAQ: TEM, 12 BUSD market cap - Sales: 700 MUSD (2024, 30% growth from previous year) Sales force: Hundreds of reps, focus on oncology ® Agreement Structure + DiviTum® TK will be included in Tempus Al onc
Slide 19: Pharma Service Update
>. et ld eer Pharma Service Update
Slide 20: Pharma Services lessons learned
DOO ® Positives + DiviTum® TKa works great in the clinical trials for several different targeted treatments. - >20 pharma companies see’s the value and are using TKa in optimize clinical trials. Increase in Tier1 lately. » Projects/Work Orders are increasing in size, 2x vs prior year. - >70% of cust
Slide 21: The Pharma Services & Collaboration Business
@ The Pharma Services & Collaboration Business | 4) Supporting pharma companies developing new cancer therapies 1. Service & Kit Sales 2. CDx Collaborations 3. CDx Product Sales Support during pre-clinical and + Co-development of complementary + CDx product on the market clinical trials phase diagno
Slide 22: Europe Update
Europe Update
Slide 23: Lessons Learned from two years on European Market
Lessons Learned from two years on European Market ® Positives Biovica has signed agreements with three strong partners covering 17 key markets! Positive development in US and Pharma Services has enabled Biovica attract partners of larger size and potential. Agreements are signed on price level confi
Slide 24: & me o S © — i
& me o S © — i
Slide 25: Financial guidance (MSEK)
@)__‘ Financial guidance (MSEk) Revenue / Area FY24/25 FY25/26 FY26/27 US Clinical Sales 3M 35M 100M Pharma Services 5M 15M 40M Europe Clinical Sales 0,5M 1M 10M Total 8,5M 50M 150M * OPEX: ~90 MSEK/year * Milestone goal: Cash-flow positive Q3 FY26/27
Slide 26: Financial Update
® Financial Update - Q4 2024/2025
Slide 27: YTD Acc Net Sales by Quarter vs PY (kSEK)
> aan “> ) VD) (4L) (4) (4 (E> Fr) G) G JIE) NA ) _ - 3 (+) YTD Acc Net Sales by Quarter vs PY (ksek) HO Se oa (+) (+) eT) Na, a 10000 i 7 ~~ GG ) ) ay, 9000 861 \Y hg sone 7290 7000 6287 Gey 5391 8000 4316 4027 4000 3.000 2.000 1766 1714 a ia : Qi Q2 Q3 Q4 2023/2024 Total 2024/2025 Total
Slide 28: Sales development by product 23/24 to 24/25 (kSEK)
Sales development by product 23/24 to 24/25 (kseEk) 12000 280 10000 2.165 ——— |e 8 000 7290 -1379 6 000 4000 2.000 IVD Tests (US) RUO Tests... Q4YTD 24/25 Q4YTD 23/24 IVD Kit (EU) Divitum Kits... M@ Increase Mi Decrease Mi Total
Slide 29: YTD US IVD Sales by Quarter (kSEK)
a (+) (+ (.) LO a ; * y, ( .) EY scot tT) tT) 7 ie Ne +) YTD US IVD Sales by Quarter (ksex) Cie aa ~~ @) ee -_ 3500 (+) —_ + (+) (4+ sam 3953 NY hg 2500 2046 2000 ueLo 1314 Buy 788 627 q | 500 365 n — 12 68 : a a2 Qs aa 2023/2024USIVD ™ 2024/2025 US IVD
Slide 30: Cash flow Q3 24/25 vs Q4 24/25
D(QDOQO QO @ PDED ADVE) GE Co) Cash flow Q3 24/25 vs Q4 24/25 OE (2 oO Nr, Q3 24/25 a4 24/5 ae “\ » 2 ff. SF) wy) & a, YQ ~~ = i) 7 oN fa SIL, ° _ YH) -10 -18 (> \/ “4s OO) -20 -25 @ Operating Cash flow before change in Working Capital ™ Change in Working Capital Pa OE) Oy) ~ ) D) wee ania aaa 8,5M
Slide 31: Rights Issue creates opportunity to leverage partnership agreements
Rights Issue of 280 MSEK creates opportunity to leverage recently signed partnership agreements! ® Structure ¢ Process + Fully guaranteed rights issue of min * 14th July: EGM 80,1 MSEK. Max 132,5 MSEK » 16°" July: Record date ® Guarantees: 80,1MSEK * 17% July: Annex IX disclosure document + Top Unde
Slide 32: Rights issue — Investors & UoP
Rights issue — Investors & UoP ® Anchor investors (Top & Subscr.) - ADutch Family Office, -40 MSEK + Has been a shareholder since 2024. * Has a desire to be represented in Board of Directors. » CEO Anders Rylander — 10 MSEK - Other Swedish investors and existing shareholders — 19,1 MSEK ® Bottom Und
Slide 33: Summary & Q&A
@ Summary & QA ©2023 33
Slide 34: Summary and upcoming milestones
@) Summary and upcoming milestones ® Key Achievements ® Upcoming milestones FDA 510(k) clearance. - Extending application to include Adjuvant Breast CLIA lab & Medicare price Cancer as LDT test from CLIA Lab Establish DiviTum TKa as standard of care at Clinical data supporting monitoring of adjuvant
Slide 35: Q&A Session
Q&A Session Financial Analysts on today’s call: ¢ Johan Unnérus - RedEye 35 Live event Q&A © x Featured® My questions to l ee Ask a moderator Questions won't be visible to everyone until a moderator approves them Question??? ] Post as anonymous
Slide 36: Questions from Q&A
Questions from Q&A when do you expect the first result of the Anonymous User (Guest) fér 10 m sedan trial at the large IDN ct Will any of the shares through the 64 © Anonymous User (Guest) fer 19 m sedan guaranteed commitments in the share issue be secured hence subject to margin calls? e 4 © ® The
Slide 37: Slide 37
Biovica International — Q4 2025 Earnings Presentation on 6ix